EYECARE: Eye Health CooperVision's SightGlass Business Reports Trial Data Indicating Vision Diffusion Optics Technology Demonstrates ‘Significant Reduction in Myopia Progression’ After Two Years By Staff Thursday, October 7, 2021 12:27 AM Executives at the SightGlass Vision Diffusion Optics Technology launch event in The Netherlands earlier this week. SAN RAMON, Calif.—CooperVision said its SightGlass Vision business has revealed two-year clinical study data for its Diffusion Optics Technology, which is specifically designed to slow the progression of myopia in children. After two years, children who wore their Diffusion Optics Technology-enabled spectacles full time, including not removing them for near vision activities, progressed on average one-half diopter less than those wearing the control spectacles—a reduction of 59 percent, according to an announcement. The new study findings were presented during a launch event in the Netherlands earlier this week, timed with the world’s first commercial launch of the technology. The new product will be available from CooperVision to eyecare professionals in the Netherlands beginning this month. (It will be the first time CooperVision has marketed a spectacle lens.) EssilorLuxottica, which will also introduce its own branded spectacle lenses with Diffusion Optics Technology, participated in the presentation, the announcement noted. Earlier this year, CooperCompanies and EssilorLuxottica announced their intent to form a joint venture to accelerate the commercialization of technologies from SightGlass Vision, as VMAIL reported. This joint venture is not yet "operational," a spokesman told VMAIL. In their February announcement, EssilorLuxottica and CooperCompanies said they will leverage their shared expertise and global leadership in myopia management to accelerate the commercialization of SightGlass Vision spectacle lenses. Through this partnership, they will further strengthen innovation opportunities and go-to-market capabilities to grow the myopia control category, the announcement noted. The CYPRESS clinical study enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D. After two years of wear, 85 percent of children wearing the innovative spectacle lenses showed less than one diopter of myopia progression. Moreover, the study also showed that 41 percent of the children wearing spectacle lenses with Diffusion Optics Technology showed no clinically meaningful progression in refractive error after two years versus only 17 percent in the control group. The CYPRESS trial is now continuing into its third year. “Our team has been singularly focused on advancing medical science to not only correct children’s vision, but also to help slow the progression of myopia. Applying our Diffusion Optics Technology to spectacle lenses makes myopia management straightforward to integrate within eyecare practices and easy to become part of children’s everyday lives,” Joe Rappon, OD, MS, FAAO, chief medical officer for SightGlass Vision, said. Spectacle lenses incorporating SightGlass Vision Diffusion Optics Technology already hold a CE Mark declaration to help slow the progression of myopia.